Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.58 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.58 |
| ▸ | XDH | P47989 | 3/20 | 0.50 |
| ▸ | CTSV | O60911 | 4/20 | 0.47 |
| ▸ | CTSL | P07711 | 4/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7159304 | 0.83 | SRD5A2 (0.82) | SRD5A2SRD5A1XDHCTSVCTSL | |
| SCHEMBL5829229 | 0.83 | SRD5A2 (0.82) | SRD5A2SRD5A1XDHCTSVCTSL | |
| SCHEMBL5017116 | 0.82 | SRD5A2 (0.63) | SRD5A2SRD5A1XDHCTSVCTSL | |
| SCHEMBL187450 | 0.81 | SRD5A2 (0.64) | SRD5A2SRD5A1XDHFLT3KDM4E | |
| SCHEMBL2722311 | 0.77 | CTSV (0.54) | CTSVCTSLABCB1ALDH1A1MEN1 | |
| SCHEMBL8406972 | 0.76 | FLT3 (0.70) | SRD5A2SRD5A1XDHCTSVCTSL | |
| SCHEMBL751415 | 0.76 | KMT2A (0.62) | CTSVCTSLABCB1ALDH1A1HPGD | |
| SCHEMBL6599162 | 0.76 | KDM4E (0.77) | SRD5A2SRD5A1XDHFLT3KDM4E | |
| SCHEMBL527105 | 0.76 | MYC (0.59) | CTSVCTSLABCB1ALDH1A1HPGD | |
| SCHEMBL30082879 | 0.76 | MYC (0.59) | CTSVCTSLABCB1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378431-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-05-27 | — | — | US | disclosed |
| US-7375116-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-05-20 | — | — | US | disclosed |
| US-7365083-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-04-29 | — | — | US | disclosed |
| US-7361670-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-04-22 | — | — | US | disclosed |
| US-20050159451-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-07-21 | — | — | US | disclosed |
| US-6919355-B2 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2005-07-19 | — | — | US | disclosed |
| US-20050113359-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20050113361-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20050113360-A1 | Amide derivatives as NMDA receptor antagonists | HORVATH CSILLA (HU) | 2005-05-26 | — | — | US | disclosed |
| US-20030199552-A1 | Amide derivatives as NMDA receptor antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113361-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | SRD5A2 2039/4885SRD5A1 1415/4885XDH 1180/4885 |
| US-20050113360-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | SRD5A2 1673/4885SRD5A1 1280/4885XDH 1107/4885 |
| US-20050159451-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | SRD5A2 2563/4885SRD5A1 1945/4885XDH 1443/4885 |
| US-20050113359-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2B | SRD5A2 2040/4885SRD5A1 1427/4885XDH 1361/4885 |
| US-20030199552-A1 | Amide derivatives as NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2C | SRD5A2 729/4885SRD5A1 432/4885XDH 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.